Press Releases from AOP Orphan Pharmaceuticals & Lantibio (1 total)
AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with No …
VIENNA, Austria and CHAPEL HILL, N.C., US, March 7 -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") and Lantibio, Inc. ("Lantibio") today announced positive final results from their placebo controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis ("CF"). Moli1901 is being developed by AOP Orphan in Europe under a licensing and commercialization agreement with Lantibio. The study, performed at multiple centers in Europe,…
